MS treatment Plegridy™(peginterferon beta-1a) approved in EU

[MSUK]

Biogen Idec has announced that the European Commission (EC) has granted marketing authorization for PlegridyTM (peginterferon beta-1a) as a treatment for adults with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). Plegridy is dosed once every two weeks and is administered subcutaneously with the Plegridy Pen, a new ready-to-use autoinjector, or a prefilled syringe..... Read More - http://www.ms-uk.org/PEGylatedinterferonbeta